A compound of general formula (I) wherein A is selected from the groups consisting of A1 and A2 R 1 is H or is selected from the group consisting of -NR 3 C(O)R 4 and -NR 3 R 3 ; X 1 and X 2 are independently N or CH; R 2 is aryl optionally substituted by one or more groups selected from halogen atoms, -(C 1 -C 6 )alkyl, cycloalkyl and -(C 1 -C 4 )haloalkyl or R 2 is heteroaryl optionally substituted by one or more halogen atoms; R 3 is H or -(C 1 -C 6 )alkyl; R 3' is H or -(C 1 -C 6 )alkyl; R 4 is selected from the group consisting of -(C 1 -C 6 )alkyl, -NR A R B , -(C 1 -C 6 )alkylene-NR A R B , -(C 1 -C 6 )alkylene-O-(C 1- C 6 )alkyl, -NH(C 1 -C 6 )alkylene-heterocycloalkyl and -(C 1 -C 6 )alkylene-heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more groups selected from oxo, alkoxy, -(C 1- C 6 )alkylene-OH, -C(O)O-(C 1 -C 6 )alkyl, -(C 1- C 6 )alkylene-C(O)O-(C 1 -C 6 )alkyl, -(C 1- C 6 )alkylene-C(O)NH-(C 1- C 6 )alkyl, -(C 1- C 6 )alkylene-C(O)NH-(C 1- C 6 )alkyl-OH, -(C 1- C 6 )alkylene-NHSO 2 -(C 1- C 6 )alkyl, -(C 1- C 6 )alkylene-CONH 2 , -(C 1 -C 6 )alkylene-NR A R B , and -(C 1 -C 6 )alkyl; R A is H or is selected from the group consisting of -(C 1 -C 6 )alkyl, heterocycloalkyl and -(C 1 -C 6 )hydroxyalkyl; R B is selected from the group consisting of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-C(O)O-(C 1 -C 6 )alkyl, heterocycloalkyl, -(C 1 -C 6 )alkylene-heterocycloalkyl, -SOz-(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-NH-SO 2 -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-SO 2 -(C 1- C 6 )alkyl and -(C 1 -C 6 )hydroxyalkyl, wherein said heterocycloalkyl of the -(C 1 -C 6 )alkylene-heterocycloalkyl may be optionally substituted by one or more -(C 1 -C 6 )alkyl; R 5 is H or selected from the group consisting of -NH 2 , -C(O)OH, -C(O)O-(C 1- C 6 )alkyl, -(C 1 -C 6 )haloalkyl and -OH; and pharmaceutically acceptable salts thereof. A is selected from the groups consisting of A1 and A2 R 1 is H or is selected from the group consisting of -NR 3 C(O)R 4 and -NR 3 R 3 ; X 1 and X 2 are independently N or CH; R 2 is aryl optionally substituted by one or more groups selected from halogen atoms, -(C 1 -C 6 )alkyl, cycloalkyl and -(C 1 -C 4 )haloalkyl or R 2 is heteroaryl optionally substituted by one or more halogen atoms; R 3 is H or -(C 1 -C 6 )alkyl; R 3' is H or -(C 1 -C 6 )alkyl; R 4 is selected from the group consisting of -(C 1 -C 6 )alkyl, -NR A R B , -(C 1 -C 6 )alkylene-NR A R B , -(C 1 -C 6 )alkylene-O-(C 1- C 6 )alkyl, -NH(C 1 -C 6 )alkylene-heterocycloalkyl and -(C 1 -C 6 )alkylene-heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted by one or more groups selected from oxo, alkoxy, -(C 1- C 6 )alkylene-OH, -C(O)O-(C 1 -C 6 )alkyl, -(C 1- C 6 )alkylene-C(O)O-(C 1 -C 6 )alkyl, -(C 1- C 6 )alkylene-C(O)NH-(C 1- C 6 )alkyl, -(C 1- C 6 )alkylene-C(O)NH-(C 1- C 6 )alkyl-OH, -(C 1- C 6 )alkylene-NHSO 2 -(C 1- C 6 )alkyl, -(C 1- C 6 )alkylene-CONH 2 , -(C 1 -C 6 )alkylene-NR A R B , and -(C 1 -C 6 )alkyl; R A is H or is selected from the group consisting of -(C 1 -C 6 )alkyl, heterocycloalkyl and -(C 1 -C 6 )hydroxyalkyl; R B is selected from the group consisting of -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-C(O)O-(C 1 -C 6 )alkyl, heterocycloalkyl, -(C 1 -C 6 )alkylene-heterocycloalkyl, -SOz-(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-NH-SO 2 -(C 1 -C 6 )alkyl, -(C 1 -C 6 )alkylene-SO 2 -(C 1- C 6 )alkyl and -(C 1 -C 6 )hydroxyalkyl, wherein said heterocycloalkyl of the -(C 1 -C 6 )alkylene-heterocycloalkyl may be optionally substituted by one or more -(C 1 -C 6 )alkyl; R 5 is H or selected from the group consisting of -NH 2 , -C(O)OH, -C(O)O-(C 1- C 6 )alkyl, -(C 1 -C 6 )haloalkyl and -OH; and pharmaceutically acceptable salts thereof. <EOS>